PRIME MEDICINE INC (PRME)

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 175 full-time employees. The company went IPO on 2022-10-20. The firm is leveraging its prime editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted deoxyribonucleic acid (DNA) modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Its Prime Editors have two main components that act together to edit DNA: a Prime Editor protein, having a Cas protein and a reverse transcriptase enzyme that may be fused together, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company is progressing a diversified portfolio of about 18 programs initially focused on genetic diseases.

Company Info

PRIME MEDICINE INC

21 Erie Street

Cambridge MASSACHUSETTS

P: 16174650013

Employees: 175

Website: https://primemedicine.com/